CYAD.BR

Celyad Oncology SA [CYAD.BR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CYAD.BR Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 50.57%

Earnings are expected to fall -100% next year

Does not have any significance market cap ($12.69M)

CYAD.BR has less than 1 year of cash runway

Top 10 Correlated ETFs

CYAD.BR

In the News

CYAD.BR Financial details

Company Rating

Neutral

Market Cap

12.69M

Income

-41.7M

Revenue

102K

Book val./share

-0.36

Cash/share

0.24

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

03 May 2024

P/E

-0.2

Forward P/E

PEG

P/S

P/B

1.91

P/C

1.36

P/FCF

-0.34

Quick Ratio

1.31

Current Ratio

1.42

Debt / Equity

-1.63

LT Debt / Equity

-1.61

EPS (TTM)

-1.81

EPS next Y

EPS next Q

EPS this Y

-81.77%

EPS next Y

EPS next 5Y

EPS last 5Y

-32.12%

Revenue last 5Y

76.23%

Revenue Q/Q

31.82%

EPS Q/Q

-5.88%

SMA20

-5.56%

SMA50

-17.07%

SMA100

-37.04%

Inst Own

Inst Trans

ROA

-208%

ROE

-171%

ROC

-4.4%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.2975-1.28

52W High

52W Low

RSI

41.44

Rel Volume

0.1

Avg Volume

25.09K

Volume

2.6K

Perf Week

-8.94%

Perf Month

-9.7%

Perf Quarter

-45.85%

Perf Half Y

-55.22%

Beta

1.296

Volatility

0.01%, 0.01%

Prev Close

-2.54%

Price

0.326

Change

3.82%

CYAD.BR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-2.29	-1.26	-1.7	-1.81	-0.33
Operating cash flow per share	-2.25	-1.98	-1.71	-1.24	-0.59
Free cash flow per share	-2.3	-2.01	-1.73	-1.25	-0.63
Cash per share	3.14	1.24	1.92	0.55	0.27
Book value per share	3.64	2.22	2.8	0.19	-0.4
Tangible book value per share	0.75	-0.37	0.48	0.15	-0.4
Share holders equity per share	3.64	2.22	2.8	0.19	-0.4
Interest debt per share	0.38	0.28	0.19	0.02	0.66
Market cap	121.47M	92.3M	54.85M	11.43M	10.03M
Enterprise value	86.5M	78.7M	27.46M	-757.46K	20.72M
P/E ratio	-4.24	-5.27	-2.07	-0.28	-1.19
Price to sales ratio	20.25K	18.46K	0	0	98.35
POCF ratio	-4.31	-3.34	-2.06	-0.41	-0.66
PFCF ratio	-4.21	-3.3	-2.03	-0.41	-0.62
P/B Ratio	2.66	2.98	1.26	2.65	-0.97
PTB ratio	2.66	2.98	1.26	2.65	-0.97
EV to sales	14.42K	15.74K	0	0	203.1
Enterprise value over EBITDA	-3.15	-3.25	-1.07	0.04	-2.11
EV to operating cash flow	-3.07	-2.84	-1.03	0.03	-1.36
EV to free cash flow	-3	-2.81	-1.02	0.03	-1.28
Earnings yield	-0.24	-0.19	-0.48	-3.58	-0.84
Free cash flow yield	-0.24	-0.3	-0.49	-2.46	-1.61
Debt to equity	0.1	0.12	0.06	0.06	-1.63
Debt to assets	0.05	0.06	0.03	0.01	1.03
Net debt to EBITDA	1.27	0.56	1.07	0.65	-1.09
Current ratio	3.59	1.67	2.48	1.42	3.79
Interest coverage	-85.64	-88.35	-103.49	-207.4	-126.15
Income quality	0.98	1.61	1	0.68	1.8
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.45K	1.8K	0	0	0
Research and developement to revenue	4.21K	4.32K	0	0	38.05
Intangibles to total assets	0.4	0.55	0.45	0.04	0
Capex to operating cash flow	0.02	0.01	0.01	0	0.06
Capex to revenue	-103.67	-63.8	0	0	-9.16
Capex to depreciation	-0.35	-0.17	-0.26	-0.09	-1.18
Stock based compensation to revenue	462.5	556.4	0	0	0
Graham number	13.69	7.92	10.34	2.79	1.72
ROIC	-0.54	-0.7	-0.54	-8.48	-1.41
Return on tangible assets	-0.53	-0.59	-0.61	-2.17	-0.52
Graham Net	-0.23	-1.18	-0.29	-0.09	-0.68
Working capital	30.91M	7.87M	20.47M	4.4M	8.19M
Tangible asset value	9.42M	-5.18M	7.47M	3.45M	-10.33M
Net current asset value	-1.38M	-15.39M	-2.01M	-574K	-15.49M
Invested capital	0.1	0.12	0.06	0.06	-1.63
Average receivables	1.53M	1.8M	1.62M	1.8M	2.02M
Average payables	6.44M	5.85M	5.67M	5.68M	3M
Average inventory	1	781.5K	781.5K	0.5	0.5
Days sales outstanding	164.37K	66.21K	0	0	9.95K
Days payables outstanding	0	0	1.59K	1.2K	-576.49
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0.01	0	0	0.04
Payables turnover	0	0	0.23	0.3	-0.63
Inventory turnover	0	0	0	1.44M	0
ROE	-0.63	-0.56	-0.61	-9.48	0.82
Capex per share	-0.05	-0.02	-0.03	-0.01	-0.04

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-03-31	2022-06-30	2022-12-31	2023-06-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.34	-0.29	-1.19	-0.17	-0.16
Operating cash flow per share	0	-0.73	-0.52	-0.37	-0.24
Free cash flow per share	0	-0.74	-0.52	-0.38	-0.26
Cash per share	0.92	0.65	0.55	0.22	0.24
Book value per share	1.64	1.38	-0.55	0.05	-0.36
Tangible book value per share	1.64	-0.27	-0.58	0.02	-0.36
Share holders equity per share	1.64	1.38	-0.55	0.05	-0.36
Interest debt per share	0.11	0.1	0.75	0.02	0.58
Market cap	47.67M	38.71M	11.43M	11.79M	11.27M
Enterprise value	29.55M	26.49M	15.87M	7.35M	21.96M
P/E ratio	-1.58	-1.52	-0.11	-0.79	-0.6
Price to sales ratio	0	0	0	268.05	194.33
POCF ratio	0	-2.37	-0.98	-1.42	-1.64
PFCF ratio	0	-2.36	-0.98	-1.36	-1.51
P/B Ratio	1.31	1.26	-0.93	11.57	-1.09
PTB ratio	1.31	1.26	-0.93	11.57	-1.09
EV to sales	0	0	0	167.14	378.55
Enterprise value over EBITDA	-3.96	-3.48	-1.32	-1.36	-4.99
EV to operating cash flow	0	-1.62	-1.36	-0.88	-3.2
EV to free cash flow	0	-1.61	-1.35	-0.85	-2.95
Earnings yield	-0.16	-0.16	-2.35	-0.32	-0.42
Free cash flow yield	0	-0.42	-1.03	-0.74	-0.66
Debt to equity	0.07	0.07	-1.36	0.53	-1.63
Debt to assets	0.03	0.03	0.85	0.04	1.03
Net debt to EBITDA	2.43	1.61	-0.37	0.82	-2.43
Current ratio	2.58	1.71	1.42	1.26	3.79
Interest coverage	-119.83	-102	-175.89	-277.33	-76.08
Income quality	0	1.16	0.44	2.23	1.46
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	79.3	0
Research and developement to revenue	0	0	0	40.27	36.36
Intangibles to total assets	0.52	0.58	0.04	0.05	0
Capex to operating cash flow	0	0.01	0	0.04	0.08
Capex to revenue	0	0	0	-7.95	-10.07
Capex to depreciation	0	-0.11	-0.04	-0.88	-1.47
Stock based compensation to revenue	0	0	0	10.09	0
Graham number	3.53	2.98	3.82	0.41	1.14
ROIC	-0.18	-0.18	-2.72	-2.71	-0.64
Return on tangible assets	-0.23	-0.24	-1.43	-0.32	-0.29
Graham Net	-0.44	-0.76	-0.83	-0.2	-0.61
Working capital	15.96M	8.02M	4.4M	1.6M	8.19M
Tangible asset value	526K	-5.94M	-13.18M	374K	-10.33M
Net current asset value	-6.64M	-13.11M	-17.21M	-3.47M	-15.49M
Invested capital	0.07	0.07	-1.36	0.53	-1.63
Average receivables	2.84M	3.53M	0	0	0
Average payables	6.06M	5.76M	0	0	0
Average inventory	-1.07M	-1.63M	0	0	0
Days sales outstanding	0	0	0	4.29K	4.31K
Days payables outstanding	0	556.87	911.9	696.12	265.09
Days of inventory on hand	0	-301.24	0	0	0
Receivables turnover	0	0	0	0.02	0.02
Payables turnover	0	0.16	0.1	0.13	0.34
Inventory turnover	0	-0.3	469K	0	0
ROE	-0.21	-0.21	2.18	-3.67	0.46
Capex per share	0	0	0	-0.02	-0.02

CYAD.BR Frequently Asked Questions

What is Celyad Oncology SA stock symbol ?

Celyad Oncology SA is a BE stock and trading under the symbol CYAD.BR

What is Celyad Oncology SA stock quote today ?

Celyad Oncology SA stock price is $0.326 today.

Is Celyad Oncology SA stock public?

Yes, Celyad Oncology SA is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Same Price Range

Similar Market Cap

Company Profile

Volume Average 25.09K
Market Capitalization 12.69M
Employee 17
CEO Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME
Headquarters Mont-Saint-Guibert,BE
IPO Date 2013-07-04
Website https://www.celyad.com

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.